All In Biotech

Drug Trial Radar · NCT06315738

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Randomized, Controlled, Phase 1-2 Open Label Study of ST266 IV Administration to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 19, 2024

Primary completion

Jun 2029

Study completion Nov 2029

Sponsor

Sponsor type
Industry
Collaborators
Parexel
First posted
Mar 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 weeks, up to 8 weeks
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the safety and tolerability of two dose levels (0.5 mL/kg and 1.0 mL/kg) of once daily (QD) via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC by incidence of treatment emergent adverse events (TEAEs) and SAEs, with a secondary objective to assess preliminary efficacy of the same two dose levels (0.5 mL/kg and 1.0 mL/kg) of QD via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC.

Conditions

  • Necrotizing Enterocolitis

Interventions

  • ST266Biological

    Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability endpoint: incidence of adverse eventsTime frame: From date of randomization through 24 months of age
  2. Safety and Tolerability endpoint: incidence of serious adverse eventsTime frame: From date of randomization through 24 months of age
  3. Safety and Tolerability endpoint: Changes in labs and vitals relative to disease progressionTime frame: From date of randomization through 24 months of age

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Yale-New Haven Hospital

    New Haven, Connecticut · Recruiting

  • BayCare Health System-St. Joseph's Women's Hospital

    Tampa, Florida · Recruiting

  • NorthShore University-Evanston Hospital

    Evanston, Illinois · Recruiting

  • Oklahoma Children's Hospital

    Oklahoma City, Oklahoma · Recruiting

  • Penn State Health Milton S Hershey Medical Center/Penn State University College of Medicine

    Hershey, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center Magee Womens Hospital

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.